

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
10 August 2023 (10.08.2023)



(10) International Publication Number
WO 2023/150566 A1

(51) International Patent Classification:

C07K 14/475 (2006.01) A61K 48/00 (2006.01)
A61K 38/17 (2006.01) C12N 15/86 (2006.01)

(21) International Application Number:

PCT/US2023/061769

(22) International Filing Date:

01 February 2023 (01.02.2023)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/305,838	02 February 2022 (02.02.2022)	US
63/336,191	28 April 2022 (28.04.2022)	US
63/336,789	29 April 2022 (29.04.2022)	US
63/339,795	09 May 2022 (09.05.2022)	US
63/435,103	23 December 2022 (23.12.2022)	US

(71) Applicant: ADVERUM BIOTECHNOLOGIES, INC.

[US/US]; 100 Cardinal Way, Redwood City, California
94063 (US).

(72) Inventors: HANNA, Kelly; 100 Cardinal Way, Redwood

City, California 94063 (US). SCHAEFER-SWALE, Kel-
lie; 100 Cardinal Way, Redwood City, California 94063
(US). RILEY, Brigit; 100 Cardinal Way, Redwood City,
California 94063 (US). GRISHANIN, Ruslan; 100 Cardi-
nal Way, Redwood City, California 94063 (US). TURPCU,
Adam; 100 Cardinal Way, Redwood City, California 94063
(US). BECKMAN, Richard; 100 Cardinal Way, Redwood
City, California 94063 (US).

(74) Agent: WHITING, Adam et al.; FisherBroyles, LLP, 4100

Redwood Rd. 20A-203, Oakland, California 94619 (US).

(81) Designated States (unless otherwise indicated, for every

kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE,
KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU,
LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG,
NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS,
RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every

kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ,
TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU,
TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE,
DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU,
LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI,
SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))

(54) Title: METHODS OF TREATING OCULAR NEOVASCULAR DISEASES USING AAV2 VARIANTS ENCODING
AFLIBERCEPT

(57) Abstract: Provided are methods for treating an ocular neovascular disease in an individual, comprising administering a unit dose of recombinant adeno-associated virus (rAAV) particles to an eye of the individual, wherein the rAAV particles comprise: a) a nucleic acid encoding a polypeptide comprising an amino acid sequence with at least about 95% identity to the amino acid sequence of SEQ ID NO: 35 and flanked by AAV2 inverted terminal repeats (ITRs), and b) an AAV2 capsid protein comprising an amino acid sequence LGGETTRP (SEQ ID NO: 14) inserted between positions 587 and 588 of the capsid protein, wherein the amino acid residue numbering corresponds to an AAV2 VP1 capsid protein.



WO 2023/150566 A1